[{"id":"c7e5810a-f6b0-478a-bc59-909bacd32f26","acronym":"TIVolBrain","url":"https://clinicaltrials.gov/study/NCT06779890","created_at":"2025-02-25T20:10:11.644Z","updated_at":"2025-02-25T20:10:11.644Z","phase":"Phase 4","brief_title":"Effect of Volatile- Based Versus Total Intravenous Anesthesia on Brain Homeostasis and Neurocognitive Outcome","source_id_and_acronym":"NCT06779890 - TIVolBrain","lead_sponsor":"Georgia Tsaousi","biomarkers":" GFAP","pipe":"","alterations":" ","tags":["GFAP"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 07/30/2026","study_completion_date":" 07/30/2026","last_update_posted":"2025-01-17"},{"id":"e083e3f6-9297-475c-8844-e43c062a3d0a","acronym":"DAANCE","url":"https://clinicaltrials.gov/study/NCT06749210","created_at":"2025-02-26T07:40:40.489Z","updated_at":"2025-02-26T07:40:40.489Z","phase":"Phase 2","brief_title":"DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY","source_id_and_acronym":"NCT06749210 - DAANCE","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" IL6 • TNFA • IL10 • BDNF • GFAP","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL10 • BDNF • GFAP"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 09/01/2030","primary_completion_date":" 09/01/2030","study_txt":" Completion: 09/01/2030","study_completion_date":" 09/01/2030","last_update_posted":"2025-01-06"},{"id":"83026695-d43a-4653-bca6-29f8b4ee5021","acronym":"REVOLUMAB","url":"https://clinicaltrials.gov/study/NCT03925246","created_at":"2021-01-18T19:18:33.109Z","updated_at":"2025-02-25T14:28:20.050Z","phase":"Phase 2","brief_title":"Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas","source_id_and_acronym":"NCT03925246 - REVOLUMAB","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" PD-L1 • TMB • IDH1 • IDH2 • MGMT • CD8 • PD-1 • ATRX • CD163 • CD4 • CD68 • FOXP3 • GFAP • OLIG2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation • IDH1 R132","tags":["PD-L1 • TMB • IDH1 • IDH2 • MGMT • CD8 • PD-1 • ATRX • CD163 • CD4 • CD68 • FOXP3 • GFAP • OLIG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • temozolomide"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 07/30/2019","start_date":" 07/30/2019","primary_txt":" Primary completion: 12/02/2020","primary_completion_date":" 12/02/2020","study_txt":" Completion: 08/18/2021","study_completion_date":" 08/18/2021","last_update_posted":"2024-04-02"},{"id":"599244a2-d49a-4ac8-ad37-8cc5d403d09c","acronym":"LSD","url":"https://clinicaltrials.gov/study/NCT04488874","created_at":"2021-01-18T21:34:13.153Z","updated_at":"2024-07-02T16:35:37.295Z","phase":"Phase 3","brief_title":"Sodium Lactate and Brain Relaxation (LSD)","source_id_and_acronym":"NCT04488874 - LSD","lead_sponsor":"Centre Hospitalier Universitaire de Besancon","biomarkers":" GFAP","pipe":"","alterations":" ","tags":["GFAP"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 09/29/2020","start_date":" 09/29/2020","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 06/30/2023","study_completion_date":" 06/30/2023","last_update_posted":"2023-09-13"},{"id":"1d76bd59-1106-4b42-9f95-8ec48f34176c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05366569","created_at":"2022-05-09T11:56:31.025Z","updated_at":"2024-07-02T16:35:42.352Z","phase":"","brief_title":"Bio-CAR-T BS Study","source_id_and_acronym":"NCT05366569","lead_sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","biomarkers":" IL6 • IL2 • IL10 • FAP • IL17A • IL23A • IL22 • GFAP","pipe":"","alterations":" ","tags":["IL6 • IL2 • IL10 • FAP • IL17A • IL23A • IL22 • GFAP"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 04/26/2022","start_date":" 04/26/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2023-07-21"},{"id":"c18a797f-f388-457a-8936-39bcb7181e0b","acronym":"MyBrain","url":"https://clinicaltrials.gov/study/NCT05840575","created_at":"2023-05-03T15:04:43.419Z","updated_at":"2024-07-02T16:35:49.160Z","phase":"","brief_title":"Investigating Cognitive Impairment in Young Patients With Cancer Prospectively","source_id_and_acronym":"NCT05840575 - MyBrain","lead_sponsor":"Rigshospitalet, Denmark","biomarkers":" IL6 • TNFA • IL10 • IL17A • BDNF • GFAP • NEFL","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL10 • IL17A • BDNF • GFAP • NEFL"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2023-05-02"},{"id":"307b0a46-d1a9-4d91-8597-eafd1ed96804","acronym":"","url":"https://clinicaltrials.gov/study/NCT01792310","created_at":"2023-02-21T23:01:19.635Z","updated_at":"2024-07-02T16:35:55.057Z","phase":"Phase 1/2","brief_title":"A Phase 1/2A Study of LAM561 in Adult Patients With Advanced Solid Tumours","source_id_and_acronym":"NCT01792310","lead_sponsor":"Laminar Pharmaceuticals","biomarkers":" GFAP","pipe":"","alterations":" ","tags":["GFAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Minerval (idroxioleic acid)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 09/01/2016","primary_completion_date":" 09/01/2016","study_txt":" Completion: 09/01/2016","study_completion_date":" 09/01/2016","last_update_posted":"2023-02-21"},{"id":"3aab3e90-ac52-4a3d-9955-f8be178a5260","acronym":"PBT","url":"https://clinicaltrials.gov/study/NCT05709522","created_at":"2023-02-02T16:00:29.287Z","updated_at":"2024-07-02T16:35:56.562Z","phase":"","brief_title":"Neurocognitive and Psychosocial Outcomes Among Pediatric Brain Tumor and Blood Cancer Patients","source_id_and_acronym":"NCT05709522 - PBT","lead_sponsor":"Aga Khan University","biomarkers":" GFAP • S100B","pipe":"","alterations":" ","tags":["GFAP • S100B"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 11/20/2020","start_date":" 11/20/2020","primary_txt":" Primary completion: 11/30/2023","primary_completion_date":" 11/30/2023","study_txt":" Completion: 11/30/2023","study_completion_date":" 11/30/2023","last_update_posted":"2023-02-02"},{"id":"023d7486-556b-40da-8c05-bb4e4cc643cc","acronym":"ACON","url":"https://clinicaltrials.gov/study/NCT05605951","created_at":"2022-11-04T16:58:19.695Z","updated_at":"2024-07-02T16:36:01.028Z","phase":"","brief_title":"Acute Optic Neuritis Network: an International Study That Invesitages Subjects With a First-ever Episode of Acute Inflammation of the Optic Nerve","source_id_and_acronym":"NCT05605951 - ACON","lead_sponsor":"Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecul","biomarkers":" GFAP","pipe":"","alterations":" ","tags":["GFAP"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 08/15/2020","start_date":" 08/15/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2022-11-04"},{"id":"f0b0e333-75aa-4854-b7f2-839721cf93b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05305092","created_at":"2022-03-31T16:52:39.507Z","updated_at":"2024-07-02T16:36:07.335Z","phase":"","brief_title":"Assessment of Brain Cognitive Impairment in Breast Cancer","source_id_and_acronym":"NCT05305092","lead_sponsor":"Tang-Du Hospital","biomarkers":" VEGFA • IL10 • BDNF • GFAP","pipe":"","alterations":" ","tags":["VEGFA • IL10 • BDNF • GFAP"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 05/31/2022","start_date":" 05/31/2022","primary_txt":" Primary completion: 05/30/2027","primary_completion_date":" 05/30/2027","study_txt":" Completion: 05/30/2027","study_completion_date":" 05/30/2027","last_update_posted":"2022-07-13"},{"id":"79fef83e-ac13-4874-b7a3-0c752d745345","acronym":"","url":"https://clinicaltrials.gov/study/NCT05232357","created_at":"2022-02-09T16:52:50.298Z","updated_at":"2024-07-02T16:36:15.417Z","phase":"Phase 1","brief_title":"Endoscopic Vital Nerve Staining in Gastrointestinal Diseases","source_id_and_acronym":"NCT05232357","lead_sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","biomarkers":" GFAP","pipe":"","alterations":" ","tags":["GFAP"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 05/01/2022","primary_completion_date":" 05/01/2022","study_txt":" Completion: 05/15/2022","study_completion_date":" 05/15/2022","last_update_posted":"2022-03-15"},{"id":"d44e9d43-8d97-4a5b-9d02-1d8ee9f9ca7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04180046","created_at":"2021-01-18T20:23:03.391Z","updated_at":"2024-07-02T16:36:32.087Z","phase":"","brief_title":"Utility of Primary Glioblastoma Cell Lines","source_id_and_acronym":"NCT04180046","lead_sponsor":"Neuromed IRCCS","biomarkers":" IDH1 • MGMT • ATRX • GFAP","pipe":" | ","alterations":" MGMT promoter methylation","tags":["IDH1 • MGMT • ATRX • GFAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 06/26/2019","start_date":" 06/26/2019","primary_txt":" Primary completion: 06/26/2019","primary_completion_date":" 06/26/2019","study_txt":" Completion: 12/30/2021","study_completion_date":" 12/30/2021","last_update_posted":"2021-04-12"},{"id":"95e88aed-1a54-4151-954e-904b2f14ffd7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02878707","created_at":"2021-01-18T14:07:55.525Z","updated_at":"2024-07-02T16:36:40.776Z","phase":"","brief_title":"The Neuroprotective Effects of Dexmedetomidine During Brain Surgery","source_id_and_acronym":"NCT02878707","lead_sponsor":"National Taiwan University Hospital","biomarkers":" HMGB1 • GFAP","pipe":"","alterations":" ","tags":["HMGB1 • GFAP"],"overall_status":"Completed","enrollment":" Enrollment 160","initiation":"Initiation: 04/24/2017","start_date":" 04/24/2017","primary_txt":" Primary completion: 04/14/2020","primary_completion_date":" 04/14/2020","study_txt":" Completion: 04/14/2020","study_completion_date":" 04/14/2020","last_update_posted":"2020-09-22"}]